NeuroSigma's CEO Leon Ekchian said, "We are delighted to inaugurate this partnership with KT. KT's expertise and capabilities in electronic and digital healthcare are a perfect complement for the Monarch eTNS System, which represents the convergence of medicine and electrical engineering. We look forward to working with KT to develop the next generations of the product to enhance the design, functionality, and user-experience and to unlock additional value from the technology by leveraging KT's core competencies and digital healthcare platform."
Checkmate Capital Group served as strategic and commercial advisor to NeuroSigma in connection with this transaction.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
KT Corporation (KRX: 030200;NYSE: KT), Korea's largest telecommunications service provider, reestablished in 1981 under the Telecommunications Business Act, is leading the era of innovation in the world's most connected country. The company is leading the 4th industrial revolution with high speed wire/wireless networks and new ICT technology. KT launched the world's first nationwide commercial 5G network on April 3, 2019, after successfully showcasing the world's first trial 5G services at the Pyeong Chang Winter Olympic Games in February 2018. This is another milestone in KT's continuous efforts to deliver essential products and services as it aspires to be the number one ICT Company and People's Company. For more information about KT Corporation, please visit www.kt.com.
NeuroSigma is a Los Angeles, California-based life sciences company established to develop bioelectronic technologies with the potential to transform medical practice and patients' lives. It has developed the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. NeuroSigma is focused on trigeminal nerve stimulation (TNS) bioelectronics therapies based on intellectual property, licensed on an exclusive basis from the University of California, Los Angeles (UCLA), being developed to treat a wide spectrum of neurological and neuropsychiatric disorders, including ADHD, drug-resistant epilepsy, post-traumatic stress disorder, and depression. TNS therapy operates through mild electrical stimulation of branches of the trigeminal nerve, including branches located near the surface of the forehead. Functional neuroimaging data suggests the mechanism of action of TNS is related to its ability to modulate activity in targeted brain regions. For more information about NeuroSigma, please visit www.neurosigma.com. For more information on eTNS, please visit www.monarch-etns.com.
Back to HCB News